Goldman Sachs Initiates Coverage On TCR2 Therapeutics with Buy Rating, Announces Price Target of $30
Goldman Sachs analyst Salveen Richter initiates coverage on TCR2 Therapeutics (NASDAQ:TCRR) with a Buy rating and announces Price Target of $30.
98 Biotechnology Stocks Moving In Wednesday’s Session
Gainers • Neurotrope, Inc. (NASDAQ:NTRP) stock increased by 131.7% to $3.36 during Wednesday’s regular session. • Genprex, Inc.…
116 Healthcare Stocks Moving In Wednesday’s Session
Gainers • Neurotrope, Inc. (NASDAQ:NTRP) stock moved upwards by 133.1% to $3.38 during Wednesday’s regular session. • Genprex,…